MDRNA Shrinks Board of Directors
Luke Timmerman5/21/09
MDRNA (NASDAQ: MRNA), the Bothell, WA-based developer of RNA interference drugs, said today it has reduced its board from eight members to five as part of its cash conservation efforts. Former CEO Steven Quay, Alex Cross, and Jack Pollack are off the new board, while Bruce Thaw, Dan Peters, James Rothman, Greg Sessler, and CEO J. Michael French will remain on the board, after yesterday’s annual shareholder meeting.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
